Sanofi, Innovent Biologics Collaborate On Cancer Treatments In China
Innovent Biologics Inc (OTC:IVBXF) and Sanofi SA (NASDAQ:SNY) have collaborated to develop and commercialize two Sanofi clinical-stage oncology assets – Phase 3 SAR408701…
Looking Into Sanofi’s Recent Short Interest
Sanofi's (NASDAQ:SNY) short percent of float has fallen 25.0% since its last report. The company recently reported that it has 2.31 million shares sold short, which is 0.09% of all regular shares that are available for trading.
Regeneron’s Prostate Cancer Combo Candidate Shows Encouraging Anti-Tumor Activity
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned $9.77 per share for Q2 FY22, down 62% Y/Y, beating the $9.54 estimate. Sales decreased…
Daily Biotech Pulse: GSK’s Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion’s Schizophrenia Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Outlook For Sanofi
Sanofi (NASDAQ:SNY) is set to give its latest quarterly earnings report on Thursday, 2022-07-28. Here's what investors need to know before the announcement.
Analysts estimate that Sanofi will report an earnings per share (EPS) of $0.87.
Regeneron’s Price Target Cut On Dim Prospects For Its Flagship Eye Product
SVB has cut the price target from $738 to $630 and downgraded from Outperform to Market Perform to reflect Regeneron Pharmaceutical Inc’s (NASDAQ:REGN)…
Rona Therapeutics Announced Exclusive Licensing Transaction from Sanofi for its Broad siRNA Therapeutic Portfolio and Technology Platform
Rona Therapeutics, Inc ("Rona"), a fully integrated platform company dedicated to the discovery, development and manufacturing of RNA therapeutics, today announced that it has obtained worldwide exclusive rights to Sanofi's siRNA platform of chemical modification and delivery moiety as well as rights to four pre-clinical candidates for undisclosed targets.
Apple, Meta, Pfizer Among Key Companies Reporting In The Week Ahead, As Earnings Pick Up Pace
Big tech earnings will flow in thick and fast in the upcoming week, providing more clarity on how supply chain disruptions and the macroeconomic malaise have impacted these companies.
Innate Pharma Announced That Sanofi Has Made Decision to Progress IPH6401/SAR’514 Into Investigational New Drug-enabling Studies, Triggering €3M Milestone Payment
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that Sanofi has made the decision to progress IPH6401/SAR'514 into investigational new drug (IND)-enabling studies, triggering a €3 million milestone payment.